Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. Sigmoidoscopy and alternative strategies

American Journal of Gastroenterology

Volumn 108, Issue 1, 2013, Pages 120-132

  Sharaf, Ravi N ^a,b   Ladabaum, Uri ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SIGMOIDOSCOPY; UNITED STATES;

COLONOSCOPY; COLORECTAL NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; OCCULT BLOOD; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGMOIDOSCOPY; UNITED STATES;

EID: 84872049747     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.380     Document Type: Article

References (100)

1. Benson VS, Patnick J, Davies AK et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008; 122: 1357-67.
2. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71.
4. Mandel JS, Church TR, Bond JH et al. Th e effect of fecal occultblood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7.
5. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
6. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
7. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
8. Zauber AG, Winawer SJ, O ' Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687-96.
9. Edwards BK, Ward E, Kohler BA et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544-73.
10. Screening for colorectal cancer: US. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-37.
11. Podolsky DK. Going the distance-the case for true colorectal-cancer screening [comment] [editorial]. N Engl J Med 2000; 343: 207-8.
12. Lieberman DA, Weiss DG, Bond JH et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Aff airs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-8.
13. Schoenfeld P, Cash B, Flood A et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352: 2061-8.
14. Baxter NN, Goldwasser MA, Paszat LF et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150: 1-8.
15. Brenner H, Hoff meister M, Arndt V et al. Protection from right-and left-sided colorectal neoplasms aft er colonoscopy: population-based study. J Natl Cancer Inst 2010; 102: 89-95.
16. Singh H, Nugent Z, Demers AA et al. Th e reduction in colorectal cancer mortality aft er colonoscopy varies by site of the cancer. Gastroenterology 2010; 139: 1128-37.
17. Singh H, Turner D, Xue L et al. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006; 295: 2366-73.
18. Mulder SA, van Soest EM, Dieleman JP et al. Exposure to colorectal examinations before a colorectal cancer diagnosis: a case-control study. Eur J Gastroenterol Hepatol 2010; 22: 437-43.
19. Neugut AI, Lebwohl B. Colonoscopy vs sigmoidoscopy screening: getting it right. JAMA 2010; 304: 461-2.
20. Baxter NN, Warren JL, Barrett MJ et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012; 30: 2664-9.
21. Brenner H, Chang-Claude J, Seiler CM et al. Protection from colorectal cancer aft er colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154: 22-30.
22. Pignone M, Saha S, Hoerger T et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104.
23. Ladabaum U, Chopra CL, Huang G et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001; 135: 769-81.
24. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 2005; 129: 1151-62.
25. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008; 27: 697-712.
26. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared to conventional colorectal cancer ccreening methods: A decision analysis. Gastroenterology 2004; 126: 1270-9.
27. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-57.
28. Segnan N, Armaroli P, Bonelli L et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst 2011; 103: 1310-22.
29. Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.
30. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. Th e National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-81.
31. Siegel JE, Weinstein MC, Russell LB et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339-41.
32. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8.
33. Lipscomb J, Weinstein MC, Torrance GW. Time preference, In: Gold MR, Siegel JE, Russell LB, Weinstein MC, (eds). Cost-effectiveness in Health and Medicine. Oxford University Press: New York, NY, 1996, pp. 214-35.
34. Briggs A, Claxton K, Sculpher M. Making decision models probabilistic. Decision Modelling for Health Economic Evaluation. Oxford University Press: Cambridge, MA, 2006, pp. 77-120.
35. Richardson LC, Rim SH, Plescia M et al. Vital signs: colorectal cancer screening among adults aged 50-75 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59: 808-12; http://www. cdc. gov/mmwr/preview/mmwrhtml/mm5926a3. htm.
36. Liang SY, Phillips KA, Nagamine M et al. Rates and predictors of colorectal cancer screening. Prev Chronic Dis 2006; 3: A117.
37. Phillips KA, Liang SY, Ladabaum U et al. Trends in colonoscopy for colorectal cancer screening. Med Care 2007; 45: 160-7.
38. Shapiro JA, SeeffLC, Th ompson TD et al. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 1623-30.
39. Etzioni DA, Yano EM, Rubenstein LV et al. Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum 2006; 49: 1002-10.
40. Myers RE, Turner B, Weinberg D et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med 2004; 38: 375-81.
41. Nadel MR, Berkowitz Z, Klabunde CN et al. Fecal occult blood testing beliefs and practices of US primary care physicians: serious deviations from evidence-based recommendations. J Gen Intern Med 2010; 25: 833-9.
42. Paszat L, Rabeneck L, Kiefer L et al. Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project. Can J Gastroenterol 2007; 21: 379-82.
43. Turner B, Myers RE, Hyslop T et al. Physician and patient factors associated with ordering a colon evaluation aft er a positive fecal occult blood test. J Gen Intern Med 2003; 18: 357-63.
44. Yabroff KR, Washington KS, Leader A et al. Is the promise of cancerscreening programs being compromised? Quality of follow-up care aft er abnormal screening results. Med Care Res Rev 2003; 60: 294-331.
45. Steinwachs D, Allen JD, Barlow WE et al. National Institutes of Health state-of-the-science conference statement: enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010; 152: 663-7.
46. Baxter NN, Sutradhar R, Forbes SS et al. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology 2011; 140: 65-72.
47. Donohoe M. Cost-effectiveness of colorectal cancer screening. JAMA 2001; 285: 407; author reply 8.
48. Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706.
49. Zubarik R, Ganguly E, Benway D et al. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. Am J Gastroenterol 2002; 97: 3056-61.
50. Centers for Disease Control and Prevention. Vital signs: colorectal cancer screening among adults aged 50-75 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59: 808-12.
51. Inadomi JM, Vijan S, Janz NK et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med 2012; 172: 575-82.
52. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101: 1412-22.
53. Howard DH, Kauh J, Lipscomb J. Th e value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med 2010; 170: 537-42.
54. Wong YN, Meropol NJ, Speier W et al. Cost implications of new treatments for advanced colorectal cancer. Cancer 2009; 115: 2081-91.
55. Yabroff KR, Mariotto AB, Feuer E et al. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ 2008; 17: 947-59.
56. Centers for Medicare and Medicaid Services. Physician Fee Schedule 2010. http://www. cms. gov/PhysicianFeeSched. Accessed 2 November 2010.
57. Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795-803.
58. Rex DK, Petrini JL, Baron TH et al. Quality indicators for colonoscopy. Am J Gastroenterol 2006; 101: 873-85.
59. Lieberman D, Nadel M, Smith RA et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 2007; 65: 757-66.
60. Lieberman D. Quality in medicine: raising the accountability bar. Gastrointest Endosc 2011; 73: 561-6.
61. Joseph DA, Degroff AS, Hayes NS et al. Th e Colorectal Cancer Control Program: partnering to increase population level screening. Gastrointest Endosc 2011; 73: 429-34.
62. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155: 1741-8.
63. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32, 702 veterans. Ann Intern Med 1995; 123: 904-10.
64. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-511; discussion 11-3.
65. Ladabaum U, Phillips KA. Colorectal cancer screening: differential costs for younger versus older Americans. Am J Prev Med 2006; 30: 378-84.
66. Ladabaum U, Song K, Fendrick AM. Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact? Clin Gastroenterol Hepatol 2004; 2: 554-63.
67. Centers for Medicare and Medicaid Services. Inpatient Prospective Payment System 2010. http://www. cms. gov/AcuteInpatientPPS/. Accessed 2 November 2010.
68. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule 2010. http://www. cms. gov/ClinicalLabFeeSched/. Accessed 2 November 2010.
69. Centers for Disease Control and Prevention. Life Tables. Vital Statistics of the United States, Preprint of Vol II, Mortality, part A, section 6 National Center for Health Statistics: Hyattsville, MD, 2003.
70. Segnan N, Senore C, Andreoni B et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005; 97: 347-57.
71. Kuroda RY, Yamada A, Furuta Y et al. A Frontal cingulotomy reconsidered from a WGA-HRP and c-Fos study in cat. Acta Neurochirurgica 1995; 64 (Supplementum): 69-73.
72. Zauber AG, Lansdorp-jVogelaar I, Wilschut J et al. Technology Assessment: Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models 2007, available online at http://www. cms. gov/medicare-coverage-database/details/technology-assessments-details. aspx?TAId=52.
73. Vatn MH, Stalsberg H. Th e prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982; 49: 819-25.
74. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982; 23: 835-42.
75. Clark JC, Collan Y, Eide TJ et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985; 36: 179-86.
76. Arminski TC, McLean MD. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1, 000 autopsy examinations. Dis Colon Rectum 1964; 7: 249-61.
77. Rickert RR, Auerbach O, Garfinkel L et al. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 1979; 43: 1847-57.
78. Wagner JL, Tunis S, Brown M et al. Cost-effectiveness of colorectal cancer screening in average risk adults. In: Young G, Rozen P, Levin B, (eds). Prevention and Early Detection of Colorectal Cancer. WB Saunders: Philadelphia, 1996, pp. 321-56.
79. Ries LAG, Kosary CL, Hankey BF et al. (eds). SEER Cancer Statistics Review, 1973-1994, NIH Pub. No. 97-2789, National Cancer Institute: Bethesda, MD, 1997.
80. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2006; 4: 808-21.
81. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
82. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
83. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
84. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
85. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87.
86. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. II Phase trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
87. Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
88. Whitlock EP, Lin JS, Liles E et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
89. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-9.
90. van Rijn JC, Reitsma JB, Stoker J et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101: 343-50.
91. Pickhardt PJ, Choi JR, Hwang I et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349: 2191-200.
92. Pignone M, Rich M, Teutsch SM et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 137: 132-41.
93. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med 2008; 149: 659-69.
94. Levin TR, Conell C, Shapiro JA et al. Complications of screening flexible sigmoidoscopy. Gastroenterology 2002; 123: 1786-92.
95. Atkin WS, Cook CF, Cuzick J et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-300.
96. Gatto NM, Frucht H, Sundararajan V et al. Risk of perforation aft er colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003; 95: 230-6.
97. Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. Am J Gastroenterol 2000; 95: 3418-22.
98. Rabeneck L, Paszat LF, Hilsden RJ et al. Bleeding and perforation aft er outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; 135: 1899-906, 906 e1.
99. Arora G, Mannalithara A, Singh G et al. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc 2009; 69 (3 Pt 2): 654-64.
100. Ramsey SD, Andersen MR, Etzioni R et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-303.